This effect could be the basis of a promising therapeutic strategy for the treatment of certain pathologies affecting cardiac (cardiac arrhythmias) or neuronal (epilepsy, Alzheimer disease or ataxia) cells, in which a downregulation of KV4.3 or DREAM has been demonstrated (Huo et al., 2014; Hall et al., 2015; Smets et al., 2015; Villa and Combi, 2016). This evidence concerns the gene KCNIP3 and early-onset autosomal dominant Alzheimer disease.